|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.00 SEK | +1.21% |
|
-3.10% | +42.86% |
| Capitalization | 858M 91.11M 78.32M 73.37M 68.39M 126M 8.2B 137M 331M 3.87B 342M 335M 14.16B | P/E ratio 2025 * |
-8.9x | P/E ratio 2026 * | -14.1x |
|---|---|---|---|---|---|
| Enterprise value | 1.27B 135M 116M 109M 101M 187M 12.14B 203M 490M 5.73B 506M 495M 20.96B | EV / Sales 2025 * |
2.48x | EV / Sales 2026 * | 2.63x |
| Free-Float |
80.61% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Orexo AB
More recommendations
More press releases
| 1 day | +1.21% | ||
| 1 week | -3.10% | ||
| Current month | -3.10% | ||
| 1 month | -8.59% | ||
| 3 months | +7.07% | ||
| 6 months | +35.14% | ||
| Current year | +42.86% |
| 1 week | 24.15 |  | 26.4 |
| 1 month | 24.15 | | 29.7 |
| Current year | 12.5 | | 43.4 |
| 1 year | 12.5 | | 43.4 |
| 3 years | 8.44 | | 43.4 |
| 5 years | 8.44 | | 56.6 |
| 10 years | 8.44 | | 87.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 53 | 2013-02-04 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 58 | 2022-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 2022-10-25 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2001-12-31 | |
George Wilkinson
BRD | Director/Board Member | 69 | 2019-04-10 |
Christine Rankin
BRD | Director/Board Member | 61 | 2022-03-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.21% | -3.10% | +66.67% | +33.98% | 91.11M | |
| +1.21% | +4.18% | -13.65% | -31.61% | 61.02B | |
| -1.01% | -3.33% | +4.07% | -19.78% | 8.57B | |
| +0.60% | -11.30% | +31.77% | +13.21% | 7.45B | |
| -1.69% | -4.15% | +28.72% | +84.57% | 7.12B | |
| -0.93% | -3.85% | +0.34% | +122.97% | 5.94B | |
| +1.50% | +4.52% | +212.18% | +67.16% | 4.38B | |
| +0.61% | -3.01% | -13.95% | -4.68% | 2.84B | |
| +1.29% | +0.20% | +23.49% | +28.28% | 2.62B | |
| -0.67% | +1.50% | +21.67% | +62.21% | 2.54B | |
| Average | +0.21% | -1.81% | +36.13% | +35.63% | 10.26B | |
| Weighted average by Cap. | +0.61% | +1.09% | +6.42% | -1.46% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 512M 54.36M 46.73M 43.77M 40.8M 75.36M 4.89B 81.97M 198M 2.31B 204M 200M 8.45B | 503M 53.41M 45.91M 43.01M 40.09M 74.05M 4.81B 80.54M 194M 2.27B 200M 196M 8.3B |
| Net income | -97.1M -10.31M -8.86M -8.3M -7.74M -14.29M -928M -15.55M -37.49M -438M -38.69M -37.87M -1.6B | -61.2M -6.5M -5.59M -5.23M -4.88M -9.01M -585M -9.8M -23.63M -276M -24.39M -23.87M -1.01B |
| Net Debt | 412M 43.74M 37.6M 35.22M 32.83M 60.64M 3.94B 65.96M 159M 1.86B 164M 161M 6.8B | 464M 49.26M 42.35M 39.67M 36.97M 68.29M 4.43B 74.28M 179M 2.09B 185M 181M 7.66B |
More financial data
* Estimated data
Employees
104
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 25.00 kr | +1.21% | 42,210 |
| 25-12-04 | 24.70 kr | -2.95% | 34,932 |
| 25-12-03 | 25.45 kr | -1.93% | 17,772 |
| 25-12-02 | 25.95 kr | -1.70% | 28,439 |
| 25-12-01 | 26.40 kr | +2.33% | 25,048 |
Delayed Quote Nasdaq Stockholm, December 05, 2025 at 12:00 pm
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ORX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition